Filing Flows › Jazz Pharmaceuticals (JAZZ) › Free cash flow
Jazz Pharmaceuticals (JAZZ) free cash flow by quarter
Jazz Pharmaceuticals' free cash flow was $490M in Q3 2026 (third quarter 2026), +23% from Q2 2026. Over the last 7 quarters it ranged from $75.9M (Q2 2025) to $490M (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $490M | +23% | +7% |
| Q2 2026 | $398M | +2% | +424% |
| Q1 2026 | $388M | +12% | -7% |
| Q4 2025 | $346M | -25% | — |
| Q3 2025 | $460M | +505% | — |
| Q2 2025 | $75.9M | -82% | — |
| Q1 2025 | $416M | — | — |
Q3 2026 at a glance
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
Questions
What is Jazz Pharmaceuticals' free cash flow?
Jazz Pharmaceuticals' free cash flow was $490M in Q3 2026 (third quarter 2026), +23% from Q2 2026.
How has Jazz Pharmaceuticals' free cash flow changed?
Over the last 7 quarters it ranged from $75.9M (Q2 2025) to $490M (Q3 2026).